Up­dat­ed: New da­ta from a mas­sive Parkin­son’s tri­al could lead to break­throughs in drug de­vel­op­ment

US sci­en­tists af­fil­i­at­ed with the Michael J. Fox Foun­da­tion — named af­ter the Back to the Fu­ture ac­tor di­ag­nosed with Parkin­son’s dis­ease in 1991 — say they can mea­sure a pro­tein that plays a role in Parkin­son’s dis­ease, in a de­vel­op­ment that foun­da­tion CEO Deb­bie Brooks called “a ma­jor break­through.”

The study mea­sured a ver­sion of al­pha-synu­cle­in in pa­tient’s cere­brospinal flu­id, which opens up the pro­tein as a bio­mark­er for fu­ture di­ag­nos­tics and drug de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER